Selbstbeschreibung: "We are a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T cell receptors (TCRs). Our lead program, utilizing our NY-ESO TCR therapeutic, has generally been well tolerated in Phase 1/2 trials in solid tumors and in hematologic cancer types and we have seen responses and preliminary evidence of tumor reduction in patients with highly refractory cancers. We continue to build a pipeline of TCR therapeutic candidates targeting a number of additional cancer targets, including our MAGE-A10 therapy in relation to which we expect to file an IND in 2015."
Britisches Understatement, dem deutschem Hochmut mit US-Wagnis entwachsen - meines Erachtens ein "Underpromise"-Langfristinvest mit vielen Chancen zu Kurzfristgewinnen durch "Overdelivery". weiteres unter www.adaptimmune.com
Founded in July 2008, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor proteins (TCRs) as a ...
Unbedingt zum Lesen und Beurteilen empfohlen - Börsenprospekt zum Depüt an der NASDAQ am 6.5.2015. Ausgabekurs $17 - Eröffnungkurs $19,50 - Schluss $16
OXFORD, UK and PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP) today announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. The aggregate net proceeds to Adaptimmune, after underwriting ...
iTechDachs
: Adaptimmune professionalisiert sich weiter
diesmal mit einem "alten Hasen" als VP Investor Relations kommt von ehemals MedImmune. Hier darf man in Zukunft wohl eine Betreuung als Investor erwarten, wie sie sonst nur die Big Pharma und etablierte BioTech Firmen bieten.
Adaptimmune Ltd, a U.K. biotechnology company that is working on treatments that use a patient’s own immune system to combat cancer, raised $191 million from an initial public offering of shares priced at the top end of expectations on Tuesday night.
Wall Street’s seemingly insatiable appetite for biotechnology stocks has led to a surge in small companies from Europe listing in the U.S., where they can fetch higher valuations than in their home markets.
OXFORD, England and PHILADELPHIA, May 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an ...
Get News First. Profit Faster With Benzinga Professional get unlimited access to ALL content! PLUS: REALTIME NEWSFEED REALTIME AUDIO NEWS FULL CALENDAR ...
Innovation Enterprise is an independent B2B multi channel media brand, focused on the information needs of Big Data, Analytics, Strategy, Digital, Innovation, Finance and Supply & Demand executives.
|
Thread abonnieren
